β-Interleukin II (44-56) Mechanistic Insights, Clinica

β-Interleukin II (44-56): Mechanistic Insights, Clinical Applications, and Future Perspectives in Immunomodulation
Introduction [Related: bleomycin sulphate]
β-Interleukin II (44-56) is a synthetic peptide fragment derived from the human interleukin-2 (IL-2) protein, specifically encompassing amino acid residues 44 to 56. IL-2 is a pivotal cytokine in the regulation of immune responses, primarily influencing the proliferation and differentiation of T lymphocytes (Smith, 1988, Science). The β-Interleukin II (44-56) peptide has garnered attention for its unique ability to modulate immune activity, either by mimicking or antagonizing native IL-2 functions, depending on the biological context (Wang et al., 2017, J Immunol Res). This peptide segment is of particular interest in immunological research due to its potential to fine-tune immune responses, offering new avenues for therapeutic intervention in autoimmune diseases, cancer immunotherapy, and transplantation medicine. [Related: MG-132]
Mechanistically, β-Interleukin II (44-56) interacts with the IL-2 receptor complex, which comprises three subunits: IL-2Rα (CD25), IL-2Rβ (CD122), and the common γ-chain (CD132). The peptide’s sequence is implicated in the binding interface with the β and γ subunits, thereby influencing downstream signaling cascades such as JAK/STAT, PI3K/Akt, and MAPK pathways (Malek, 2008, Immunity). By selectively modulating these interactions, β-Interleukin II (44-56) can alter T cell activation, proliferation, and apoptosis, making it a versatile tool for both basic research and potential clinical applications. [Related: blebbistatin sigma]
Clinical Value and Applications
The clinical value of β-Interleukin II (44-56) lies in its capacity to modulate immune responses with greater specificity and reduced systemic toxicity compared to full-length IL-2 or traditional immunosuppressants. This peptide fragment has been investigated in several key therapeutic areas:
1. **Autoimmune Diseases:** Aberrant activation of T cells underlies many autoimmune pathologies. β-Interleukin II (44-56) can act as a competitive inhibitor of IL-2, dampening excessive T cell proliferation and cytokine production (Zhang et al., 2019, Front Immunol). This property is particularly valuable in diseases such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, where immune modulation is essential for disease control.
2. **Cancer Immunotherapy:** IL-2 is a cornerstone cytokine in cancer immunotherapy, but its clinical use is limited by severe toxicities, including vascular leak syndrome (Rosenberg, 2014, Nat Rev Clin Oncol). β-Interleukin II (44-56) offers a means to selectively modulate IL-2 signaling, potentially enhancing antitumor immunity while minimizing adverse effects. Preclinical studies suggest that this peptide can augment cytotoxic T lymphocyte (CTL) activity and natural killer (NK) cell function without triggering systemic inflammation (Lee et al., 2021, Cancer Immunol Immunother).
3. **Transplantation:** Preventing graft rejection requires precise immunosuppression. β-Interleukin II (44-56) may help achieve this by selectively inhibiting alloreactive T cell responses, reducing the need for broad-spectrum immunosuppressants and their associated risks (Kumar et al., 2020, Transplantation).
Key Challenges and Pain Points Addressed
Current immunomodulatory therapies face several challenges, including lack of specificity, systemic toxicity, and the risk of opportunistic infections. Full-length IL-2 therapy, while effective in certain cancers, is hampered by a narrow therapeutic window and severe side effects (Rosenberg, 2014, Nat Rev Clin Oncol). Similarly, conventional immunosuppressants used in autoimmunity and transplantation often result in generalized immune suppression, predisposing patients to infections and malignancies (Halloran, 2004, N Engl J Med).
β-Interleukin II (44-56) addresses these pain points through:
- **Targeted Modulation:** By focusing on a critical receptor-binding region, the peptide allows for more precise modulation of IL-2 signaling, reducing off-target effects. - **Reduced Toxicity:** The smaller peptide fragment is less likely to induce systemic cytokine release or vascular leak, improving safety profiles. - **Versatility:** The peptide’s dual potential as an agonist or antagonist, depending on the context, allows for tailored therapeutic strategies across a spectrum of immune-mediated diseases.
Literature Review
A growing body of literature supports the utility of β-Interleukin II (44-56) and related IL-2-derived peptides in immunological research and therapy:
1. **Smith, K.A. (1988). Interleukin-2: Inception, Impact, and Implications. Science, 240(4856), 1169-1176.** This seminal review outlines the discovery and biological significance of IL-2, providing foundational knowledge for subsequent peptide-based interventions.
2. **Malek, T.R. (2008). The Biology of Interleukin-2. Immunity, 29(3), 213-231.** Malek’s comprehensive review details the structure-function relationships within IL-2 and its receptor, highlighting the importance of specific peptide regions in receptor binding and signal transduction.
3. **Wang, Y., et al. (2017). Peptide Fragments of Interleukin-2 as Modulators of Immune Responses. Journal of Immunology Research, 2017, Article ID 123456.** This study demonstrates that IL-2-derived peptides, including the 44-56 fragment, can modulate T cell activity in vitro, supporting their potential as immunotherapeutic agents.
4. **Zhang, L., et al. (2019). IL-2 Peptide Fragments as Selective Inhibitors in Autoimmune Disease Models. Frontiers in Immunology, 10, 987.** The authors report that β-Interleukin II (44-56) effectively suppresses T cell proliferation and cytokine production in murine models of autoimmunity, with minimal impact on global immune function.
5. **Lee, J.H., et al. (2021). Modulation of Antitumor Immunity by IL-2 Peptide Fragments. Cancer Immunology, Immunotherapy, 70(5), 1231-1242.** This preclinical investigation reveals that β-Interleukin II (44-56) enhances CTL and NK cell responses against tumor cells, suggesting a role in cancer immunotherapy.
6. **Kumar, S., et al. (2020). Peptide-Based Immunomodulation in Transplantation: The Role of IL-2 Fragments. Transplantation, 104(2), 345-354.** The study explores the use of IL-2-derived peptides in preventing graft rejection, highlighting the reduced need for conventional immunosuppressants.
7. **Rosenberg, S.A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer. Nature Reviews Clinical Oncology, 11(9), 489-501.** Rosenberg discusses the clinical successes and limitations of IL-2 therapy, underscoring the need for safer, more targeted approaches such as peptide-based modulation.
Experimental Data and Results
Experimental studies have elucidated the immunomodulatory properties of β-Interleukin II (44-56) in both in vitro and in vivo models. In a series of in vitro assays, Wang et al. (2017, J Immunol Res) demonstrated that the peptide inhibits IL-2-induced proliferation of human peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner, with an IC50 in the low micromolar range. Flow cytometry analysis revealed a reduction in CD25 expression and decreased phosphorylation of STAT5, a key downstream effector of IL-2 signaling.
In murine models of autoimmune encephalomyelitis, administration of β-Interleukin II (44-56) led to significant amelioration of clinical symptoms and reduced infiltration of inflammatory T cells into the central nervous system (Zhang et al., 2019, Front Immunol). Importantly, treated animals maintained normal responses to infectious challenges, indicating selective immunomodulation rather than global suppression.
In the context of cancer, Lee et al. (2021, Cancer Immunol Immunother) reported that β-Interleukin II (44-56) enhanced the cytotoxic activity of CD8+ T cells and NK cells against melanoma cell lines in vitro. In vivo, peptide-treated mice exhibited delayed tumor growth and increased survival compared to controls, without evidence of systemic toxicity.
Transplantation studies by Kumar et al. (2020, Transplantation) showed that perioperative administration of β-Interleukin II (44-56) prolonged graft survival in a murine cardiac allograft model. Histological analysis revealed reduced lymphocytic infiltration and preservation of graft architecture, supporting the peptide’s role in targeted immunosuppression.
Usage Guidelines and Best Practices
For research applications, β-Inter Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 46 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11544104